全文获取类型
收费全文 | 538篇 |
免费 | 48篇 |
国内免费 | 1篇 |
学科分类
医药卫生 | 587篇 |
出版年
2021年 | 10篇 |
2020年 | 6篇 |
2019年 | 7篇 |
2018年 | 9篇 |
2017年 | 6篇 |
2016年 | 9篇 |
2015年 | 11篇 |
2014年 | 15篇 |
2013年 | 14篇 |
2012年 | 22篇 |
2011年 | 21篇 |
2010年 | 10篇 |
2009年 | 9篇 |
2008年 | 18篇 |
2007年 | 28篇 |
2006年 | 29篇 |
2005年 | 21篇 |
2004年 | 26篇 |
2003年 | 27篇 |
2002年 | 19篇 |
2001年 | 19篇 |
2000年 | 14篇 |
1999年 | 28篇 |
1998年 | 23篇 |
1997年 | 13篇 |
1996年 | 13篇 |
1995年 | 15篇 |
1994年 | 9篇 |
1993年 | 17篇 |
1992年 | 7篇 |
1991年 | 11篇 |
1990年 | 4篇 |
1989年 | 12篇 |
1988年 | 7篇 |
1987年 | 6篇 |
1986年 | 6篇 |
1985年 | 8篇 |
1982年 | 4篇 |
1980年 | 7篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 4篇 |
1975年 | 2篇 |
1959年 | 2篇 |
1958年 | 2篇 |
1957年 | 6篇 |
1956年 | 4篇 |
1955年 | 4篇 |
1954年 | 5篇 |
1950年 | 2篇 |
排序方式: 共有587条查询结果,搜索用时 140 毫秒
581.
Yucai Wang Matthew J. Maurer Melissa C. Larson Cristine Allmer Andrew L. Feldman N. Nora Bennani Carrie A. Thompson Luis F. Porrata Thomas M. Habermann Thomas E. Witzig Stephen M. Ansell Susan L. Slager Grzegorz S. Nowakowski James R. Cerhan 《British journal of haematology》2019,186(6):820-828
The diabetes mellitus (DM) drug metformin targets mechanistic/mammalian target of rapamycin and inhibits lymphoma growth in vitro. We investigated whether metformin affected outcomes of newly diagnosed diffuse large B-cell (DLBCL, n = 869) and follicular lymphoma (FL, n = 895) patients enrolled in the Mayo component of the Molecular Epidemiology Resource cohort study between 2002 and 2015. Hazard ratios (HR) and 95% confidence intervals (CIs) adjusted for age, sex, body mass index, prognostic index and treatment were used to estimate the association of metformin exposure (No DM/No metformin; DM/No metformin; DM/Metformin) with event-free (EFS), lymphoma-specific (LSS) and overall (OS) survival. Compared to No DM/No metformin DLBCL patients, there was no association of DM/Metformin (n = 48; HR = 1·05, 95% CI 0·59–1·89) or DM/No metformin(n = 54; HR = 1·41, 95% CI 0·88–2·26) with EFS; results were similar for LSS and OS. Compared to No DM/No metformin FL patients, there was no association of DM/Metformin (n = 37; HR = 1·16, 95% CI 0·71–1·89) or DM/No metformin (n = 19; HR = 1·16, 95% CI 0·66–2·04) with EFS; results were similar for LSS. However, DM/Metformin was associated with inferior OS (HR = 2·17; 95% CI 1·19–3·95) compared to No DM/No metformin. In conclusion, we found no evidence that metformin use was associated with improved outcomes in newly diagnosed DLBCL and FL. 相似文献
582.
Leung N Gertz MA Zeldenrust SR Rajkumar SV Dispenzieri A Fervenza FC Kumar S Lacy MQ Lust JA Greipp PR Witzig TE Hayman SR Russell SJ Kyle RA Winters JL 《Kidney international》2008,73(11):1282-1288
Cast nephropathy is the most common cause of renal disease in multiple myeloma, however, treatment with plasma exchange remains controversial even after 3 randomized controlled studies. We sought to determine the importance of diagnostic confirmation and goal directed therapy in the treatment of cast nephropathy in forty patients with confirmed multiple myeloma and renal failure who underwent plasma exchange. A positive renal response was defined as a decrease by half in the presenting serum creatinine and dialysis independence. No baseline differences were noted between eventual renal responders and non-responders. Three quarters of the patients with biopsy proven cast nephropathy resolved their renal disease when the free light chains present in the serum were reduced by half or more but there was no significant response when the reduction was less. The median time to a response was about 2 months. In patients without cast nephropathy, renal recovery occurred despite reductions in free light chain levels of the serum. No association was found between free light chains in the serum, urinary monoclonal proteins, overall proteinuria and cast nephropathy. We found that the relationship between renal recovery and free light chain reduction was present only in patients with biopsy proven cast nephropathy showing the importance of extracorporeal light chain removal in this disease. 相似文献
583.
医学影像学是一门实践性很强的形象思维学科,如何合理应用多媒体技术手段开展现代医学影像学教学,本文就多媒体技术与传统板书教学的有机结合进行了有益的探讨。强调做好现代多媒体技术手段教学与传统教学的重要性是医学影像学教学一个值得重视和思考的问题。 相似文献
584.
585.
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. 总被引:9,自引:0,他引:9
A Dispenzieri M Q Lacy R A Kyle T M Therneau D R Larson S V Rajkumar R Fonseca P R Greipp T E Witzig J A Lust M A Gertz 《Journal of clinical oncology》2001,19(14):3350-3356
PURPOSE: Based on the success of hematopoietic stem-cell transplantation (HSCT) for multiple myeloma, HSCT is being used to treat patients with primary systemic amyloidosis (AL). This article addresses the extent to which eligibility to undergo HSCT is a favorable prognostic feature and explores prognostic factors within the subset of eligible patients. PATIENTS AND METHODS: The Mayo Clinic amyloid database was queried for all patients with AL seen at the Mayo Clinic from 1983 through 1997 who would have been eligible for peripheral-blood stem-cell transplantation. Inclusion criteria included biopsy-proven amyloid, symptomatic disease, absence of a clinical diagnosis of multiple myeloma, age < or = 70 years, cardiac interventricular septal thickness < or = 15 mm, cardiac ejection fraction more than 55%, serum creatinine < or = 2 mg/dL, and direct bilirubin < or = 2.0 mg/dL. RESULTS: Median age was 56 years (range, 25 to 70) with 79 (34%) older than 60 years. One hundred patients had early cardiac involvement; 41, hepatic involvement; 167, renal involvement; and 39, nerve involvement. The 229 patients have had a median follow-up of 52 months, and 151 have died. The median survival was 42 months with 5- and 10-year survival rates of 36% and 15%, respectively. Important predictors of survival were size of M-component in 24-hour urine, number of involved organs, alkaline phosphatase, performance score, and weight loss. CONCLUSION: The same patients who are eligible for HSCT are a good-risk population who do relatively well with chemotherapy (median survival, 42 months), substantially better than the expected median survival of 18 months for all patients with AL. A randomized trial is needed to assess the true effect of HSCT. 相似文献
586.
Gregory A. Wiseman Christine A. White Michael Stabin William L. Dunn William Erwin Magnus Dahlbom Andrew Raubitschek Kastytis Karvelis Timothy Schultheiss Thomas E. Witzig Richard Belanger Stewart Spies Daniel H. S. Silverman Judy R. Berlfein Eric Ding Antonio J. Grillo-López 《European journal of nuclear medicine and molecular imaging》2000,27(7):766-777
Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to normal
organs and bone marrow from 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) treatment in this phase I/II, multicenter trial. The trial was designed
to determine the dose of Rituximab (chimeric anti-CD20, Rituxan, IDEC-C2B8, MabThera), the unlabeled antibody given prior
to the radioconjugate to clear peripheral blood B cells and optimize distribution, and to determine the maximum tolerated
dose of 90Y-Zevalin [7.4, 11, or 15 MBq/kg (0.2, 0.3, or 0.4 mCi/kg)]. Patients received 111In-Zevalin (indium-111 ibritumomab tiuxetan, IDEC-In2B8 ) on day 0 followed by a therapeutic dose of 90Y-Zevalin on day 7. Both doses were preceded by an infusion of the chimeric, unlabeled antibody Rituximab. Following administration
of 111In-Zevalin, serial anterior/posterior whole-body scans were acquired. Major-organ radioactivity versus time estimates were
calculated using regions of interest. Residence times were computed and entered into the MIRDOSE3 computer software program
to calculate estimated radiation absorbed dose to each organ. Initial analyses of estimated radiation absorbed dose were completed
at the clinical site. An additional, centralized dosimetry analysis was performed subsequently to provide a consistent analysis
of data collected from the seven clinical sites. In all patients with dosimetry data (n
=56), normal organ and red marrow radiation absorbed doses were estimated to be well under the protocol-defined upper limit
of 20 Gy and 3 Gy, respectively. Median estimated radiation absorbed dose was 3.4 Gy to liver (range 1.2–7.8 Gy), 2.6 Gy to
lungs (range 0.72–4.4 Gy), and 0.38 Gy to kidneys (range 0.07–0.61 Gy). Median estimated tumor radiation absorbed dose was
17 Gy (range 5.8–67 Gy). No correlation was noted between hematologic toxicity and the following variables: red marrow radiation
absorbed dose, blood T
1/2, blood AUC, plasma T
1/2, and plasma AUC. It is concluded that 90Y-Zevalin administered at nonmyeloablative maximum tolerated doses results in acceptable radiation absorbed doses to normal
organs. The only toxicity of note is hematologic and is not correlated to red marrow radiation absorbed dose estimates or
T
1/2, reflecting that hematologic toxicity is dependent on bone marrow reserve in this heavily pretreated population.
Received 24 January and in revised form 20 March 2000 相似文献
587.
Sanjal H. Desai Raphael Mwangi Alexandra N. Smith Matthew J. Maurer Umar Farooq Rebecca L. King James R. Cerhan Andrew L. Feldman Thomas M. Habermann Carrie A. Thompson Yucai Wang Stephen M. Ansell Thomas E. Witzig Grzegorz S. Nowakowski 《Hematological oncology》2023,41(1):39-49
Activated B cell (ABC) type diffuse large B cell lymphoma (DLBCL), double hit lymphoma (DHL) and double expressor lymphoma (DEL) have poor outcomes to frontline R-CHOP but impact of these molecular features on outcomes of relapsed/refractory (R/R) disease is not well-characterized. We evaluated the association of diagnostic cell of origin (COO), double hit and double expressor status with overall survival after first relapse in DLBCL patients who were enrolled into the Molecular Epidemiology Resource (MER) cohort. COO was available from immunohistochemistry (IHC) using Hans criteria or gene expression profiling (GEP) (Nanostring) on the diagnostic FFPE biopsy. Of 373 pts with R/R DLBCL, 278 had COO by IHC: 152 were GCB, 107 were non-GCB. One hundred and fourty had COO by GEP: 44 were ABC, 65 were GCB and 13 were unclassifiable. Nineteen out of 163 (12%) were DHL; 30 out of 135 (22%) had DEL. COO, either by IHC (2 years OS GCB: 45% [CI95: 38–54] vs. non-GCB: 44% [CI95:36–55], p > 0.05) or GEP (2 years OS ABC: 42% [CI95: 29–59] vs. GCB: 40% [CI95: 30–54], p > 0.05), was not associated with difference in OS. DHL (2 years OS 16 [CI95:6–45] vs. 45% [CI95: 34–59], p < 0.01) and DEL (2 years OS 33% [CI95: 20–56], vs. 50% [CI95: 41–60], p < 0.05) had lower OS than non-DHL and non-DEL/non-DHL counterparts, respectively. COO by IHC or GEP was not associated with OS in R/R DLBCL while DHL and DEL were adverse prognostic markers in DLBCL at first relapse. 相似文献